With a market capitalization of Rs 1,140 crores, the shares of Gujarat Themis Biosyn Limited are currently trading at Rs 784. In the last 5 trading sessions, the stock prices have moved down around 2 percent ranging from Rs 799 to the current levels.
Through a recent filing with the BSE, the company announced its financial results for the last quarter as well as annual results for FY22-23. Details of the same are discussed in the later half of the piece.
In addition, the company’s Board recommended a Final dividend of Rs 1 (20 percent of its face value of Rs 5) for FY22-23. The payment of the same is subject to the shareholder’s approval.
The Board is also considering a 1:5 stock split which refers to a sub-division of 1 equity share with a face value of Rs 5 each into 5 equity shares having a face value of Rs 1 each.
Keeping a purview of a long-term horizon of 5 years, the stock has been able to generate multibagger returns of approximately 2,000 percent for its stakeholders. It means if someone would have invested Rs 1 Lakh in the stock, it would have converted to Rs 20 Lakhs within a period of 5 years.
Gujarat Themis Biosyn Limited is engaged in the process of manufacturing pharmaceuticals and medicinal chemical products. The company’s products include Rifamycin-S, used in the treatment of tuberculosis (TB), and Lovastatin.
Having a look at the sequential numbers reported, the operating income remained at the same levels present at Rs 28.16 crores in Q3 v/s Rs 28.17 crores in Q4. Moreover, the net profits moved up from Rs 9.80 crores to Rs 11.69 crores during the same period.
On a YoY basis, both the metrics mentioned above, showed a movement in congruence with the QoQ shift with operating income increasing from Rs 115 crores during FY21-22 to Rs 149 crores in FY22-23 and net profits moving up from Rs 44 crores to Rs 58 crores.
Showcasing operational efficiencies, the company has been able to improve its net profit margins with the most recent shift being from 33.32 percent during FY20-21 to 37.98 percent in FY21-22. The debt-to-equity ratio of the company, which remained ideal during the past financial years, stands at nil as of FY21-22.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
